Contac

   
Google
 
Web NewDrugInformation.com

Contac


Drug - Contac
The trade name of the product as shown on the labeling.

Dosage - TABLET, EXTENDED RELEASE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Chlorpheniramine Maleate; Phenylpropanolamine Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - 12MG;75MG
The potency of the active ingredient(s), Chlorpheniramine Maleate; Phenylpropanolamine Hydrochloride. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Contac. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 019613
The FDA assigned number to Contac. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Contac. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 13, 1986
The date Contac was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Contac. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Contac is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Consumer Health Inc
The full name of the firm holding legal responsibility for the new application of Contac.

Contac